AIDS Reader

DOUG BALTZ

642 W STRAWN AVE

Jonesboro

72401

Articles

Select Updates From the 16th CROI: Treatment-Related Cardiovascular Risk, Pharmacokinetic Issues, and Interleukin-2 Use

April 02, 2009

The 16th Conference on Retroviruses and Opportunistic Infections (CROI) was held in Montreal from February 8 to 11, 2009. This conference provided significant new insights into HIV therapeutics. Here we summarize new findings presented on the effect of antiretroviral therapy on cardiovascular disease (CVD) risk; new pharmacokinetic data, notably, the progress in developing pharmacokinetic boosters as alternatives to low-dose ritonavir; and the lack of clinical benefit with interleukin (IL)-2.

HIV and Myelodysplasia

April 02, 2009

The manifestations of HIV infection are known to involve every organ system and aspect of pathophysiology. The bone marrow is particularly susceptible to the ravages of HIV infection; in addition to non-Hodgkin lymphoma, myelodysplasia and acute leukemia have been associated with HIV infection, although they are not considered to be AIDS-defining illnesses.1-5 Here we report the case of a 58-year-old man who presented with myelodysplasia as a primary manifestation of his HIV infection.

Skipping Doctor Visits Risky for HIV Patients, Old Drugs Might Give TB a 1-2 Punch, J & J Seeks Full Approval for Intelence

April 02, 2009

The death rate for HIV-infected patients who miss scheduled clinic appointments during their first year of treatment is more than double that for patients with perfect attendance, according to a recent study (Douglas D. Reuters Health. February 11, 2009).

HIV-Related Lipodystrophy in Africa and Asia

April 01, 2009

In 2005, members of the Group of Eight (G8)-an international forum for the governments of Canada, France, Germany, Italy, Japan, Russia, the United Kingdom, the United States, and the European Union-along with the African Union and the heads of state attending the 2005 United Nations World Summit, joined with the UNAIDS Secretariat in committing themselves to providing universal access to HIV care, prevention, and treatment for all those in need by 2010.

Fatal Progressive Multifocal Leukoencephalopathy: Still a Problem in the Era of Highly Active Antiretroviral Therapy

March 14, 2009

A 37-year-old white woman, previously in excellent health, presented to a local emergency department for evaluation of evolving left-sided weakness and a slight left facial droop.

Battle Against Virus Shows Signs of Progress, Hispanics Respond Poorly to Hepatitis C Treatment, Litigation Harmful in HIV Prevention

March 14, 2009

New data from UNAIDS show that several African countries with a high HIV prevalence have made significant gains in preventing new infections.

Editorial Comment: Tenofovir Nephrotoxicity-The Disconnect Between Clinical Trials and Real-World Practice

March 11, 2009

Although highly effective with a high benefit-to-risk ratio, highly active antiretroviral therapy has a variety of adverse effects, including metabolic, lipid, and bone toxicities. Importantly, renal toxicity has been associated with some of the more widely used agents, specifically from the NRTI and protease inhibitor classes.

Proximal Tubular Dysfunction Associated With Tenofovir and Didanosine Causing Fanconi Syndrome and Diabetes Insipidus: A Report of 3 Cases

March 10, 2009

The availability of highly active antiretroviral therapy has improved the survival and quality of life of patients infected with HIV. Clinicians are now focusing on the management of metabolic complications and previously unrecognized drug toxicities. The incidence and prevalence of kidney disease are increasing in older HIV-infected patients because of the widespread use of antiretroviral therapy.

Fatal Herpes Simplex Virus Type 2 Pneumonia in a Person With AIDS

February 27, 2009

Herpes simplex virus (HSV) is an enveloped double-stranded DNA virus that is a common pathogen in humans. There are 2 subtypes, HSV-1 and HSV-2,